pharmaceutical investing Johnson & Johnson's RYBREVANT® plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer 6h
pharmaceutical investing Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses 10 September
pharmaceutical investing Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026 08 September
